Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. more
Time Frame | REGN | Sector | S&P500 |
---|---|---|---|
1-Week Return | -6% | -2.27% | -0.57% |
1-Month Return | -9.08% | -3.96% | 1.21% |
3-Month Return | -36.59% | -9.7% | 7.57% |
6-Month Return | -28.76% | -3.37% | 11.45% |
1-Year Return | -16.53% | 3.71% | 28.48% |
3-Year Return | 10.78% | 3.8% | 29.52% |
5-Year Return | 94.28% | 39.78% | 90.66% |
10-Year Return | 82.36% | 106.91% | 203.75% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 7.86B | 8.50B | 16.07B | 12.17B | 13.12B | [{"date":"2019-12-31","value":48.93,"profit":true},{"date":"2020-12-31","value":52.87,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":75.74,"profit":true},{"date":"2023-12-31","value":81.62,"profit":true}] |
Cost of Revenue | 782.20M | 1.12B | 2.44B | 1.56B | 883.70M | [{"date":"2019-12-31","value":32.09,"profit":true},{"date":"2020-12-31","value":45.94,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":64.02,"profit":true},{"date":"2023-12-31","value":36.25,"profit":true}] |
Gross Profit | 7.08B | 7.38B | 13.63B | 10.61B | 12.23B | [{"date":"2019-12-31","value":51.94,"profit":true},{"date":"2020-12-31","value":54.11,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":77.84,"profit":true},{"date":"2023-12-31","value":89.73,"profit":true}] |
Gross Margin | 90.05% | 86.82% | 84.83% | 87.18% | 93.26% | [{"date":"2019-12-31","value":96.56,"profit":true},{"date":"2020-12-31","value":93.09,"profit":true},{"date":"2021-12-31","value":90.96,"profit":true},{"date":"2022-12-31","value":93.48,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 4.87B | 3.80B | 4.69B | 5.62B | 7.07B | [{"date":"2019-12-31","value":68.9,"profit":true},{"date":"2020-12-31","value":53.75,"profit":true},{"date":"2021-12-31","value":66.3,"profit":true},{"date":"2022-12-31","value":79.47,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | 2.21B | 3.58B | 8.95B | 4.74B | 4.05B | [{"date":"2019-12-31","value":24.7,"profit":true},{"date":"2020-12-31","value":39.98,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":52.97,"profit":true},{"date":"2023-12-31","value":45.24,"profit":true}] |
Total Non-Operating Income/Expense | 189.10M | 176.90M | 321.70M | 220.60M | 497.80M | [{"date":"2019-12-31","value":37.99,"profit":true},{"date":"2020-12-31","value":35.54,"profit":true},{"date":"2021-12-31","value":64.62,"profit":true},{"date":"2022-12-31","value":44.31,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | 2.43B | 3.81B | 9.33B | 4.86B | 4.20B | [{"date":"2019-12-31","value":26.05,"profit":true},{"date":"2020-12-31","value":40.86,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":52.1,"profit":true},{"date":"2023-12-31","value":45.03,"profit":true}] |
Income Taxes | 313.30M | 297.20M | 1.25B | 520.40M | 245.70M | [{"date":"2019-12-31","value":25.05,"profit":true},{"date":"2020-12-31","value":23.77,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":41.62,"profit":true},{"date":"2023-12-31","value":19.65,"profit":true}] |
Income After Taxes | 2.12B | 3.51B | 8.08B | 4.34B | 3.95B | [{"date":"2019-12-31","value":26.2,"profit":true},{"date":"2020-12-31","value":43.51,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":53.72,"profit":true},{"date":"2023-12-31","value":48.96,"profit":true}] |
Income From Continuous Operations | 2.12B | 3.51B | 8.08B | 4.34B | 3.99B | [{"date":"2019-12-31","value":26.2,"profit":true},{"date":"2020-12-31","value":43.51,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":53.72,"profit":true},{"date":"2023-12-31","value":49.42,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 2.12B | 3.51B | 8.08B | 4.34B | 3.95B | [{"date":"2019-12-31","value":26.2,"profit":true},{"date":"2020-12-31","value":43.51,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":53.72,"profit":true},{"date":"2023-12-31","value":48.96,"profit":true}] |
EPS (Diluted) | 24.64 | 31.65 | 71.38 | 42.40 | 43.78 | [{"date":"2019-12-31","value":34.52,"profit":true},{"date":"2020-12-31","value":44.34,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":59.4,"profit":true},{"date":"2023-12-31","value":61.33,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
REGN | |
---|---|
Cash Ratio | 2.68 |
Current Ratio | 5.28 |
Quick Ratio | 4.46 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
REGN | |
---|---|
ROA (LTM) | 7.41% |
ROE (LTM) | 17.17% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
REGN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.22 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.78 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
REGN | |
---|---|
Trailing PE | 19.12 |
Forward PE | 17.15 |
P/S (TTM) | 6.13 |
P/B | 2.90 |
Price/FCF | 77 |
EV/R | 5.62 |
EV/Ebitda | 14.15 |
PEG | 1.15 |
Regeneron Pharmaceuticals Inc (REGN) share price today is $731.3
Yes, Indians can buy shares of Regeneron Pharmaceuticals Inc (REGN) on Vested. To buy Regeneron Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in REGN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Regeneron Pharmaceuticals Inc (REGN) via the Vested app. You can start investing in Regeneron Pharmaceuticals Inc (REGN) with a minimum investment of $1.
You can invest in shares of Regeneron Pharmaceuticals Inc (REGN) via Vested in three simple steps:
The 52-week high price of Regeneron Pharmaceuticals Inc (REGN) is $1211.2. The 52-week low price of Regeneron Pharmaceuticals Inc (REGN) is $735.95.
The price-to-earnings (P/E) ratio of Regeneron Pharmaceuticals Inc (REGN) is 19.1195
The price-to-book (P/B) ratio of Regeneron Pharmaceuticals Inc (REGN) is 2.90
The dividend yield of Regeneron Pharmaceuticals Inc (REGN) is 0.00%
The market capitalization of Regeneron Pharmaceuticals Inc (REGN) is $84.94B
The stock symbol (or ticker) of Regeneron Pharmaceuticals Inc is REGN